» Articles » PMID: 27526944

New Insights into the Mode of Action of the Lantibiotic Salivaricin B

Overview
Journal Sci Rep
Specialty Science
Date 2016 Aug 17
PMID 27526944
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Salivaricin B is a 25 amino acid polycyclic peptide belonging to the type AII lantibiotics and first shown to be produced by Streptococcus salivarius. In this study we describe the bactericidal mode of action of salivaricin B against susceptible Gram-positive bacteria. The killing action of salivaricin B required micro-molar concentrations of lantibiotic whereas the prototype lantibiotic nisin A was shown to be potent at nano-molar levels. Unlike nisin A, salivaricin B did not induce pore formation or dissipate the membrane potential in susceptible cells. This was established by measuring the fluorescence of the tryptophan residue at position 17 when salivaricin B interacted with bacterial membrane vesicles. The absence of a fluorescence blue shift indicates a failure of salivaricin B to penetrate the membranes. On the other hand, salivaricin B interfered with cell wall biosynthesis, as shown by the accumulation of the final soluble cell wall precursor UDP-MurNAc-pentapeptide which is the backbone of the bacterial peptidoglycan. Transmission electron microscopy of salivaricin B-treated cells showed a reduction in cell wall thickness together with signs of aberrant septum formation in the absence of visible changes to cytoplasmic membrane integrity.

Citing Articles

Cell-free biosynthesis and engineering of ribosomally synthesized lanthipeptides.

Liu W, Ji X, Ba F, Zhang Y, Xu H, Huang S Nat Commun. 2024; 15(1):4336.

PMID: 38773100 PMC: 11109155. DOI: 10.1038/s41467-024-48726-y.


Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial.

Peng X, Li Z, Pei Y, Zheng S, Liu J, Wang J J Clin Oncol. 2024; 42(12):1426-1435.

PMID: 38215354 PMC: 11095859. DOI: 10.1200/JCO.23.00837.


Beneficial modulation of human health in the oral cavity and beyond using bacteriocin-like inhibitory substance-producing streptococcal probiotics.

Tagg J, Harold L, Jain R, Hale J Front Microbiol. 2023; 14:1161155.

PMID: 37056747 PMC: 10086258. DOI: 10.3389/fmicb.2023.1161155.


The First Lanthipeptide from Lactobacillus iners, Inecin L, Exerts High Antimicrobial Activity against Human Vaginal Pathogens.

Li L, Zhang J, Zhou L, Shi H, Mai H, Su J Appl Environ Microbiol. 2023; 89(3):e0212322.

PMID: 36847550 PMC: 10057874. DOI: 10.1128/aem.02123-22.


Antimicrobial potential of known and novel probiotics on in vitro periodontitis biofilms.

Van Holm W, Carvalho R, Delanghe L, Eilers T, Zayed N, Mermans F NPJ Biofilms Microbiomes. 2023; 9(1):3.

PMID: 36681674 PMC: 9867767. DOI: 10.1038/s41522-023-00370-y.


References
1.
Ruhr E, Sahl H . Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. Antimicrob Agents Chemother. 1985; 27(5):841-5. PMC: 180163. DOI: 10.1128/AAC.27.5.841. View

2.
Rogers L, Whittier E . LIMITING FACTORS IN THE LACTIC FERMENTATION. J Bacteriol. 1928; 16(4):211-29. PMC: 375023. DOI: 10.1128/jb.16.4.211-229.1928. View

3.
Sass V, Schneider T, Wilmes M, Korner C, Tossi A, Novikova N . Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect Immun. 2010; 78(6):2793-800. PMC: 2876548. DOI: 10.1128/IAI.00688-09. View

4.
Schmitt P, Wilmes M, Pugniere M, Aumelas A, Bachere E, Sahl H . Insight into invertebrate defensin mechanism of action: oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II. J Biol Chem. 2010; 285(38):29208-16. PMC: 2937951. DOI: 10.1074/jbc.M110.143388. View

5.
Draper L, Cotter P, Hill C, Ross R . Lantibiotic resistance. Microbiol Mol Biol Rev. 2015; 79(2):171-91. PMC: 4394878. DOI: 10.1128/MMBR.00051-14. View